Anti-Amyloid-β Protein agents for the treatment of Alzheimer’s Disease: An update on emerging drugs

The characterisation of subjective cognitive decline

(2020) Frank Jessen et al.   LANCET NEUROLOGY

Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer’s Disease?1

(2020) Ariel J. Kuhn et al.   JOURNAL OF ALZHEIMERS DISEASE

APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline

(2020) Axel Montagne et al.   NATURE

LRP1 is a master regulator of tau uptake and spread

(2020) Jennifer N. Rauch et al.   NATURE

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

(2020) Francesco Panza et al.   Nature Reviews Neurology

Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline

(2020) Joanne Ryan et al.   NEUROLOGY

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

(2020) Reisa A. Sperling et al.   JAMA Neurology

A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease

(2020) Harald Hampel et al.   Frontiers in Immunology

Early diagnosis of Alzheimer’s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts

(2020) P.M. Rossini et al.   CLINICAL NEUROPHYSIOLOGY

Amyloid-β Immunotherapy for Alzheimer's Disease - Is It Now A Long Shot…?

(2019) Francesco Panza et al.   ANNALS OF NEUROLOGY

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes

(2019) Anja Soldan et al.   NEUROLOGY

Do BACE inhibitor failures in Alzheimer’s patients challenge the amyloid hypothesis of the disease?

(2019) Francesco Panza et al.   Expert Review of Neurotherapeutics

Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease

(2019) David Henley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

(2019) Michael F. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease

(2019) Dan-Dan Li et al.   Frontiers in Neuroscience

Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia

(2019) Clifford R. Jack et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Amyloid, vascular, and resilience pathways associated with cognitive aging

(2019) Prashanthi Vemuri et al.   ANNALS OF NEUROLOGY

Time to test antibacterial therapy in Alzheimer’s disease

(2019) Francesco Panza et al.   BRAIN

Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression

(2019) Xinyi Wang et al.   CELL RESEARCH

Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin

(2019) Valentina Loconte et al.   JOURNAL OF STRUCTURAL BIOLOGY

Investigational BACE inhibitors for the treatment of Alzheimer’s disease

(2019) Bruno P. Imbimbo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

(2019) Gregory Klein et al.   Alzheimers Research & Therapy

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults

(2018) Nancy J. Donovan et al.   AMERICAN JOURNAL OF PSYCHIATRY

Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics

(2018) Brendan P. Lucey et al.   ANNALS OF NEUROLOGY

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death

(2018) Sofia Söllvander et al.   Journal of Neuroinflammation

Amyloid pathology in the progression to mild cognitive impairment

(2018) Philip S. Insel et al.   NEUROBIOLOGY OF AGING

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

(2018) Lawrence S. Honig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis

(2018) Can Zhang et al.   Scientific Reports

The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease

(2018) Holly M. Brothers et al.   Frontiers in Aging Neuroscience

Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals

(2018) Jennifer S. Rabin et al.   JAMA Neurology

Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments

(2018) Eric M. Reiman et al.   JOURNAL OF ALZHEIMERS DISEASE

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

(2018) Bernd Bohrmann et al.   JOURNAL OF ALZHEIMERS DISEASE

The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice

(2018) Stina Tucker et al.   JOURNAL OF ALZHEIMERS DISEASE

Aroylhydrazones constitute a promising class of ‘metal-protein attenuating compounds’ for the treatment of Alzheimer’s disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone

(2018) Daphne S. Cukierman et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer’s Disease

(2018) Schamim H Eckert et al.   Aging and Disease

Efficacy and safety of alisporivir for the treatment of hepatitis C infection

(2018) Carol Stanciu et al.   EXPERT OPINION ON PHARMACOTHERAPY

Peripheral immune system in aging and Alzheimer’s disease

(2018) Wei Cao et al.   Molecular Neurodegeneration

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis

(2017) Taro Kishi et al.   JOURNAL OF ALZHEIMERS DISEASE

Levetiracetam Alters Oscillatory Connectivity in Alzheimer’s Disease

(2017) Christian S. Musaeus et al.   JOURNAL OF ALZHEIMERS DISEASE

Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease

(2017) Ramakrishna Nirogi et al.   JOURNAL OF MEDICINAL CHEMISTRY

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

(2017) Susanne Ostrowitzki et al.   Alzheimers Research & Therapy

iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer’s Disease

(2017) Takayuki Kondo et al.   Cell Reports

Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?

(2017) Robert G. Struble et al.   JOURNAL OF ALZHEIMERS DISEASE

Incidence and impact of subclinical epileptiform activity in Alzheimer's disease

(2016) Keith A. Vossel et al.   ANNALS OF NEUROLOGY

Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients

(2016) Francesco Panza et al.   EXPERT OPINION ON EMERGING DRUGS

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

The amyloid cascade hypothesis: are we poised for success or failure?

(2016) Eric Karran et al.   JOURNAL OF NEUROCHEMISTRY

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

(2016) Jinping Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effects of Heart Bypass Surgery on Plasma Aβ40 and Aβ42 Levels in Infants and Young Children

(2016) Yaoqin Hu et al.   MEDICINE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models

(2015) Yvonne Bouter et al.   ACTA NEUROPATHOLOGICA

Beta-amyloid deposition in chronic traumatic encephalopathy

(2015) Thor D. Stein et al.   ACTA NEUROPATHOLOGICA

Neuroinflammation in Alzheimer's disease

(2015) Michael T Heneka et al.   LANCET NEUROLOGY

The Alzheimer disease market

(2015) XiaoXiao Qian et al.   NATURE REVIEWS DRUG DISCOVERY

An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies

(2015) Grant Coan et al.   Neurodegenerative Diseases

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

(2015)   NEUROLOGY

Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance

(2015) Arnold Bakker et al.   NeuroImage-Clinical

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

(2014) Francesco Panza et al.   Expert Review of Clinical Immunology

Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease

(2014) Francesco Panza et al.   Expert Review of Neurotherapeutics

A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease

(2014) Yukiko Hori et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

The Preclinical Alzheimer Cognitive Composite

(2014) Michael C. Donohue et al.   JAMA Neurology

Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men

(2014) Sharon Ooms et al.   JAMA Neurology

The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques

(2013) Patty C. Kandalepas et al.   ACTA NEUROPATHOLOGICA

Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease

(2013) Carolyn W. Zhu et al.   Alzheimers & Dementia

The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives

(2013) Russell H. Swerdlow et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Antiepileptics Topiramate and Levetiracetam Alleviate Behavioral Deficits and Reduce Neuropathology in APPswe/PS1dE9 Transgenic Mice

(2013) Jian-Quan Shi et al.   CNS Neuroscience & Therapeutics

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study

(2013) Joel Ross et al.   Current Alzheimer Research

Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors

(2013) Giuseppe Zanotti et al.   FEBS LETTERS

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study

(2013) Stephanie JB Vos et al.   LANCET NEUROLOGY

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial

(2013) S.M. Mills et al.   REVUE NEUROLOGIQUE

Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation

(2013) Ayman ElAli et al.   Acta Neuropathologica Communications

Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β

(2012) B. REINSFELT et al.   ACTA ANAESTHESIOLOGICA SCANDINAVICA

Rational heterodoxy: Cholesterol reformation of the amyloid doctrine

(2012) Michael A. Castello et al.   AGEING RESEARCH REVIEWS

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Benefits of combined cholinesterase inhibitor and memantine treatment in moderate–severe Alzheimer's disease

(2012) Serge Gauthier et al.   Alzheimers & Dementia

Lower CSF Amyloid Beta Peptides and Higher F2-Isoprostanes in Cognitively Intact Elderly Individuals With Major Depressive Disorder

(2012) Nunzio Pomara et al.   AMERICAN JOURNAL OF PSYCHIATRY

Soluble oligomers and fibrillar species of amyloid β-peptide differentially affect cognitive functions and hippocampal inflammatory response

(2012) Yan He et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

(2012) Bruno P Imbimbo et al.   Expert Review of Clinical Immunology

Amyloid precursor protein (APP) contributes to pathology in the SOD1G93A mouse model of amyotrophic lateral sclerosis

(2012) J. Barney Bryson et al.   HUMAN MOLECULAR GENETICS

Brain Ischemia Activates β- and γ-Secretase Cleavage of Amyloid Precursor Protein: Significance in Sporadic Alzheimer’s Disease

(2012) Ryszard Pluta et al.   MOLECULAR NEUROBIOLOGY

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A

(2012) Robert D. Bell et al.   NATURE

Deciphering the mechanism underlying late-onset Alzheimer disease

(2012) Dimitrije Krstic et al.   Nature Reviews Neurology

Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment

(2012) Arnold Bakker et al.   NEURON

3,3′,4′,5,5′-Pentahydroxyflavone is a potent inhibitor of amyloid β fibril formation

(2012) Hiroko Ushikubo et al.   NEUROSCIENCE LETTERS

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray?

(2011) Tyler A. Kokjohn et al.   Alzheimers & Dementia

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

(2011) Victor L. Villemagne et al.   ANNALS OF NEUROLOGY

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab

(2011) Francesco Panza et al.   Current Alzheimer Research

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

(2011) Grazia D'Onofrio et al.   Expert Opinion on Drug Discovery

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease

(2010) Eduardo Cumbo et al.   EPILEPSY & BEHAVIOR

Reimagining Alzheimer's Disease--An Age-Based Hypothesis

(2010) K. Herrup   JOURNAL OF NEUROSCIENCE

Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?

(2010) Victoria E. Johnson et al.   NATURE REVIEWS NEUROSCIENCE

Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study

(2009) Richard C. Mohs et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

The Common Inhalational Anesthetic Sevoflurane Induces Apoptosis and Increases β-Amyloid Protein Levels

(2009) Yuanlin Dong et al.   ARCHIVES OF NEUROLOGY

Amyloid  -Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy

(2009) R. Minkeviciene et al.   JOURNAL OF NEUROSCIENCE

Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment

(2009) Ming Teng Koh et al.   NEUROPSYCHOPHARMACOLOGY

Alzheimer Disease Pathology As a Host Response

(2008) Rudy J. Castellani et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

(2008) Rachelle S Doody et al.   LANCET

Protective effects of NSAIDs on the development of Alzheimer disease

(2008) Steven C. Vlad et al.   NEUROLOGY

Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid β protein

(2008) Tatsuhiro Akaishi et al.   NEUROSCIENCE LETTERS